Colorcon acquires Kollicot Coating Systems line from BASF
Company also advances co-operation to offer superior functional coatings for pharmaceutical tablets.
Colorcon and BASF have signed an agreement to further strengthen their co-operation in the area of pharmaceutical film coatings. As part of this agreement, BASF will sell its Kollicoat IR Coating Systems product line to Colorcon; including the current customer business, inventory and relevant know-how. The addition of the Kollicoat IR Coating Systems complements Colorcon’s existing film coating product line and position as a leading innovator of fully formulated film coating systems and provides Kollicoat IR Coating Systems customers with a wide range of film coating options. Final closure of the transaction is subject to review of the Brazilian competition authorities.
By acquiring the Kollicoat IR Coating Systems, Colorcon further strengthens its existing activities with PVA-based pigmented, ready-to-use film coatings, for use on immediate release forms of pharmaceuticals and dietary supplements. Kelly Boyer, General Manager Coatings at Colorcon, explains: “This sale enables both companies to focus on their core competencies, and further strengthens our existing cooperation.” After final closure of the transaction all existing customers of Kollicoat IR Coating Systems will be served by Colorcon from its worldwide production facilities. Both BASF and Colorcon look forward to the opportunity to expand the cooperation between both companies in the film coating area by combining BASF’s polymer expertise and Colorcon’s formulation and application knowledge. Frank Stein, Vice President Global Segment Management Pharma Solutions at BASF, states: “Customers will benefit from both the exceptional functional performance of the products as well as from Colorcon’s worldwide unique, customized services.BASF will focus on developing and promoting innovative film coating polymers including Kollicoat IR. The transfer of Kollicoat IR Coating Systems does not affect BASF’s Kollicoat IR polymer business.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance